Camac Fund, ATG Capital Management and McIntyre Capital (together 7.6%) entered into a settlement agreement with Forte Biosciences (FBRX)

Key Summary: Various investment firms, including BML Investment Partners, Camac Fund, ATG Fund, McIntyre Capital, and Funicular Funds, expressed concerns, advocated for change, and recommended actions in relation to a company's management and governance. Camac Fund, ATG Fund, and McIntyre Capital (collectively 7.6%) settled with the company and its Board on June 11, 2024. This agreement resulted in the formation of a strategic alternatives committee, an expansion of the Board to nine seats with Camac-appointed directors.

Want to read more?

Subscribe to snowballresearch.com to keep reading this exclusive post.

Subscribe Now